4-(5-(4,7-dimethylbenzo[d]oxazol-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid

ID: ALA4562084

Chembl Id: CHEMBL4562084

PubChem CID: 121432507

Max Phase: Preclinical

Molecular Formula: C18H13N3O4

Molecular Weight: 335.32

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cc1ccc(C)c2oc(-c3nc(-c4ccc(C(=O)O)cc4)no3)nc12

Standard InChI:  InChI=1S/C18H13N3O4/c1-9-3-4-10(2)14-13(9)19-16(24-14)17-20-15(21-25-17)11-5-7-12(8-6-11)18(22)23/h3-8H,1-2H3,(H,22,23)

Standard InChI Key:  VKSMQHIHCUMOQU-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA4562084

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 335.32

Molecular Weight (Monoisotopic): 335.0906

AlogP: 3.86

#Rotatable Bonds: 3

Polar Surface Area: 102.25

Molecular Species: ACID

HBA: 6

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 3.72

CX Basic pKa: ┄

CX LogP: 4.65

CX LogD: 1.32

Aromatic Rings: 4

Heavy Atoms: 25

QED Weighted: 0.61

Np Likeness Score: -0.94

References

1. Goncalves MB, Clarke E, Jarvis CI, Barret Kalindjian S, Pitcher T, Grist J, Hobbs C, Carlstedt T, Jack J, Brown JT, Mills M, Mumford P, Borthwick AD, Corcoran JPT..  (2019)  Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury.,  29  (8): [PMID:30792038] [10.1016/j.bmcl.2019.02.011]

Source

Source(1):

• Scientific Literature